This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.
Biotech investors were happy with the way the year was turning out. Then summer ended, and now, they are glum.
The XBI is still up 24%, although it’s down 11% from the August high. The retreat doesn’t look that alarming relative to the depths of the biotech winter experienced in early 2025. The real trouble, and the reason for investor angst, lies below the surface of the XBI’s performance.